Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

DESTINY-Breast03 Could Have Long-Lasting Effects on the Treatment Landscape of HER2+ Breast Cancer

May 5th 2022

Marcela Mazo Canola, MD, discusses pivotal trials in early-stage and metastatic HER2-positive breast cancer, plus ongoing trials to watch.

Recently Approved Regimens for HER2+ Metastatic Breast Cancer

May 5th 2022

Data from the HER2CLIMB, NALA, and SOPHIA trials that led to the FDA approval of respective agents in the setting of HER2+ metastatic breast cancer.

FDA Grants Regular Approval to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer

May 4th 2022

The FDA has approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.

Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer

May 4th 2022

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

May 4th 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer

May 3rd 2022

Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.

Breast Cancer Paradigm Pushes Forward With Neoadjuvant, Adjuvant Advances

May 2nd 2022

Reshma Mahtani, DO, discusses the use of antibody-drug conjugates, tyrosine kinase inhibitors, CDK4/6 inhibitors, and PARP inhibitors across HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

Considering Novel Therapy for HER2+ Metastatic Breast Cancer

April 29th 2022

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Patient Profile 2: 3L Therapy for Triple-Positive mBC

April 29th 2022

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Impact of DESTINY-Breast03 on Real-World Management of HER2+ mBC

April 28th 2022

Focusing on real-world treatment selection, Cynthia Lynch, MD, considers how the DESTINY-Breast03 trial impacted her practice and broader treatment guidelines.

HER2+ mBC: Safety Outcomes From the DESTINY-Breast03 Trial

April 28th 2022

Insight on the safety events observed in the DESTINY-Breast03 trial and how this translates to real-world adverse event management in HER2+ metastatic breast cancer.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

April 27th 2022

The FDA has granted a breakthrough therapy designation to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Cancer-Specific Mortality Is Higher Among Younger Black Female Patients With Breast Cancer

April 27th 2022

The risk of cancer-specific mortality in breast cancer was increased for younger adult Black female patients compared with younger adult White female patients.

Neoadjuvant Pembrolizumab/Chemo Followed by Adjuvant Pembrolizumab Approaches EU Approval for High-Risk, Early-Stage TNBC

April 26th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab alone after surgery for adult patients with locally advanced or early-stage triple-negative breast cancer who are at a high risk for recurrence.

Dr. Kalinsky on Strategies to Prevent Recurrence in Early Breast Cancer

April 26th 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.

Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast Cancer

April 26th 2022

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Uptake of New Therapies Pushes Treatment Paradigm Forward in Breast Cancer

April 22nd 2022

Recent developments across the breast cancer paradigm include the utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, plus neoadjuvant treatment strategies in triple-negative breast cancer.

Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Bardia Reflects on Important Data in HER2+ Breast Cancer

April 21st 2022

Dr Bardia discusses data from DESTINY-Breast03, HER2CLIMB, and NALA, important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.